{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:46:20Z","timestamp":1787013980928,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Induction chemo\u2010immunotherapy has emerged as a potential treatment option for locoregionally advanced nasopharyngeal carcinoma (LANPC). This study aimed to evaluate the efficacy and safety of camrelizumab combined with modified TPF (nab\u2010paclitaxel, cisplatin, and S\u20101) as induction chemo\u2010immunotherapy in LANPC. Patients with stage T1\u20104N2\u20103M0 NPC who received induction chemo\u2010immunotherapy were enrolled from July 2023 to May 2024. They underwent three cycles of chemo\u2010immunotherapy, including camrelizumab 200\u2009mg on day 1, nab\u2010paclitaxel 260\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    on day 1, cisplatin 25\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    on days 1\u20133, and oral S\u20101 40\u201360\u2009mg twice daily from days 1 to 14, every 21\u2009days. The primary endpoint was the complete response (CR) rate, while secondary endpoints included the safety and objective response rate (ORR). A total of 30 patients were enrolled, with 29 (96.7%) completing three cycles of induction chemo\u2010immunotherapy. The CR rate was 41.4% (12\/29), achieving the predefined endpoint. The CR rate for the primary nasopharyngeal tumor and cervical lymph nodes was both 65.5% (19\/29). Seventeen patients achieved a partial response (PR), resulting in an ORR of 100%. Grade 3 or 4 chemotherapy\u2010related adverse events occurred in 26.6% of patients. Immune\u2010related adverse events of any grade were reported in 20 (66.7%) patients, including reactive cutaneous capillary endothelial proliferation in 10 patients (40.0%), all of which were Grade 1 or 2. One patient (3.5%) experienced a Grade 3 rash. No treatment\u2010related deaths occurred. Our study suggests that induction chemo\u2010immunotherapy of camrelizumab plus modified TPF demonstrated an excellent CR rate and an acceptable safety profile in patients with LANPC.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    ChiCTR240008603\n                  <\/jats:p>","DOI":"10.1111\/cas.70037","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:36:50Z","timestamp":1741757810000},"page":"1616-1626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Induction Camrelizumab and Modified\n                    <scp>TPF<\/scp>\n                    (Nab\u2010Paclitaxel, Cisplatin, and S\u20101) in Locoregionally Advanced Nasopharyngeal Carcinoma"],"prefix":"10.1111","volume":"116","author":[{"given":"Yi\u2010Feng","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Qing","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong\u2010Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan\u2010Zhong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-8706","authenticated-orcid":false,"given":"Qin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-2614","authenticated-orcid":false,"given":"San\u2010Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine Xiamen University  Xiamen People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2196\/49968"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301496"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12113"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30410-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00327"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03237"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30520"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101625"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5545"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00594-4"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00504-7"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077890","article-title":"Nab\u2010Paclitaxel, Cisplatin, and Capecitabine Versus Cisplatin and Gemcitabine as First Line Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: Randomised Phase 3 Clinical Trial","volume":"385","author":"Liu G. Y.","year":"2024","journal-title":"BMJ"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i14.4358"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07750-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2023.05.003"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2833-5"},{"issue":"7","key":"e_1_2_11_19_1","first-page":"3445","article-title":"Nab\u2010Paclitaxel Promotes the Cancer\u2010Immunity Cycle as a Potential Immunomodulator","volume":"11","author":"Chen Y.","year":"2021","journal-title":"American Journal of Cancer Research"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0125"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S122974"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2751"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46444-z"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106867"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12852"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2073-5"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.027"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(21)00255-5"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03698-2"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00601-1"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0863-5"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02508"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2635"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.007"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102920"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6132"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12564-4"},{"key":"e_1_2_11_40_1","volume-title":"Guidelines of Chinese Society of Clinical Oncology (CSCO) Nasopharyngeal Carcinoma","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2024"},{"key":"e_1_2_11_41_1","unstructured":"National Comprehensive Cancer Network \u201cNCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers 2025 \u201d2025Version 2 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head\u2010and\u2010neck.pdf."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:06:01Z","timestamp":1748815561000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cas.70037"],"URL":"https:\/\/doi.org\/10.1111\/cas.70037","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"2024-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}